Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab ASGMAB +0.09%97 EV-to-OCF is 27.43 as of Aug. 23, 2026, which is 34% below its 10-year median of 41.55. GuruFocus rates GMAB with a GF Score™ of 97/100 and a GF Value™ of $35.68 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,407 Biotechnology companies, Genmab AS ranks worse than 91.19% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Genmab AS's Enterprise Value is $24,438 Mil.
Genmab AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $891 Mil. Therefore, Genmab AS's EV-to-OCF for today is 27.43.
The historical rank and industry rank for Genmab AS's EV-to-OCF or its related term are showing as below:
GMAB'
s EV-to-OCF Range Over the Past 10 Years
Min: 6.89 Med: 41.55 Max: 290.14
Current: 27.53
During the past 13 years, the highest EV-to-OCF of Genmab AS was 290.14. The lowest was 6.89. And the median was 41.55.
GMAB's EV-to-OCF is ranked worse than 91.19% of 1407
companies
in the Biotechnology industry
Industry Median: -3.61
vs GMAB: 27.53
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Genmab AS's share price for today is $33.45.
Genmab AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.267.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Genmab AS EV-to-OCF Related Terms
Genmab AS EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Genmab AS's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genmab AS's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genmab AS EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genmab AS's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Genmab AS's EV-to-OCF falls into.
Genmab AS's current Enterprise Value is $24,438 Mil.
Genmab AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $891 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genmab AS (GMAB) has a EV-to-OCF of 27.43 as of Aug. 23, 2026. This is 34% below median its historical median of 41.55. Over the past decade, Genmab AS's EV-to-OCF has ranged from 6.89 to 290.14. According to the industry distribution chart, Genmab AS ranks #1283 out of 1407 companies in the Biotechnology industry, placing it in the top 91.2%.
Is Genmab AS's EV-to-OCF too high?
Genmab AS's current EV-to-OCF of 27.43 is 34% below median its 10-year median of 41.55. Over the past 10 years, this metric has ranged from a low of 6.89 to a high of 290.14. Based on the distribution chart, Genmab AS ranks #1283 out of 1407 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Genmab AS has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genmab AS ranks #1283 out of 1407 companies for EV-to-OCF. This places Genmab AS in the lower half of its industry. Historically, Genmab AS's own EV-to-OCF has ranged from 6.89 to 290.14 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Genmab AS's current EV-to-OCF is 27.43, which is 34% below median its own 10-year median of 41.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GMAB) is currently considered Fairly Valued. The stock's GF Value™ is $35.68, compared to a current price of $33.45 — trading 6.2% below its estimated fair value. The current EV-to-OCF is 27.43, which is 34% below median its 10-year median of 41.55. Genmab AS's overall GF Score™ is 97/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Genmab AS (GMAB), the current EV-to-OCF is 27.43 as of Aug. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (GMAB) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of $33.45 is trading 6.2% below its estimated GF Value™ of $35.68.
GuruFocus considers Genmab AS to be Fairly Valued.
Key valuation signals for GMAB:
EV-to-OCF: 27.43 (34% below median its 10-year median of 41.55)
GF Value™: $35.68 vs. price of $33.45 (6.2% below fair value)
No single metric tells the full story. See the GMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
97GF Score
Get the complete analysis for GMAB
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GMAB has been successfully added to your 
